Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis (FingoHRV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01704183|
Recruitment Status : Completed
First Posted : October 11, 2012
Last Update Posted : May 8, 2014
The purpose of this study is to study the effect of fingolimod on cardiac autonomic regulation in patients with relapse-remitting multiple sclerosis.
This will be done by measuring heart rate variability from the 24-hour Holter recording and myocardial ventricular repolarisation patterns from the 12-lead electrocardiogram tracings.
The fingolimod treatment is prescribed according to the accepted drug label.
|Condition or disease|
|Relapse-remitting Multiple Sclerosis|
|Study Type :||Observational|
|Actual Enrollment :||27 participants|
|Official Title:||Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis|
|Study Start Date :||December 2012|
|Actual Primary Completion Date :||March 2014|
|Actual Study Completion Date :||March 2014|
- change in heart rate variability [ Time Frame: prior medication vs initiation vs 3 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01704183
|Neuro Center, Kuopio University Hospital|
|Department of Neurology, Mikkeli Central Hospital|
|Study Director:||Sakari Simula, MD, PhD||Mikkeli Central Hospital, Department of Neurology|
|Study Director:||Päivi Hartikainen, MD, PhD||Kuopio University Hospital, Neuro Center|
|Study Director:||Juha Hartikainen, MD, PhD||Kuopio University Hospital, Heart Center|